ArticleFrontiers in oncology2020

A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML.

Alexander J Ambinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.